Impact of Bimekizumab on MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis: 2-Year Results from a Phase 3 Study and its Open-Label Extension

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.